Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Oncoinvent ASA's enterprise value is kr207.17 Mil.
Oncoinvent ASA's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was kr-132.36 Mil. Therefore, Oncoinvent ASA's EV-to-EBITDA for today is -1.57.
The historical rank and industry rank for Oncoinvent ASA's EV-to-EBITDA or its related term are showing as below:
CHIX:ONCINo'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -11.59 Med: -1.39 Max: 0.89
Current: -1.56
During the past 11 years, the highest EV-to-EBITDA of Oncoinvent ASA was 0.89. The lowest was -11.59. And the median was -1.39.
CHIX:ONCINo's EV-to-EBITDA is ranked worse than 100% of 407
companies
in the Biotechnology industry
Industry Median: 13.94
vs CHIX:ONCINo: -1.56
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Oncoinvent ASA's PE Ratio (TTM) for today is calculated as:
Oncoinvent ASA's share price for today is kr1039.90731.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Oncoinvent ASA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was kr-157.076.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Oncoinvent ASA's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:ONCINO vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Oncoinvent ASA's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncoinvent ASA EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncoinvent ASA's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Oncoinvent ASA's EV-to-EBITDA falls into.
Oncoinvent ASA's current Enterprise Value is kr207.17 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Oncoinvent ASA's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was kr-132.36 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncoinvent ASA (CHIX:ONCINO) has a EV-to-EBITDA of -1.57 as of Aug. 25, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Oncoinvent ASA. According to the industry distribution chart, Oncoinvent ASA ranks #999999 out of 407 companies in the Biotechnology industry.
Is Oncoinvent ASA's EV-to-EBITDA too high?
Oncoinvent ASA's current EV-to-EBITDA is -1.57. Based on the distribution chart, Oncoinvent ASA ranks #999999 out of 407 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Oncoinvent ASA has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Oncoinvent ASA's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oncoinvent ASA ranks #999999 out of 407 companies for EV-to-EBITDA. This places Oncoinvent ASA in the lower half of its industry. The industry median EV-to-EBITDA is 13.94. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.94, based on 407 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Oncoinvent ASA. For the Biotechnology industry, the median EV-to-EBITDA is 13.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncoinvent ASA's current EV-to-EBITDA is -1.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncoinvent ASA stock overvalued right now?
Oncoinvent ASA (CHIX:ONCINO) has a current EV-to-EBITDA of -1.57. The stock's GF Value™ is kr11,980.43, compared to a current price of kr1,039.91 — trading 91.3% below its estimated fair value. The current EV-to-EBITDA is -1.57. Oncoinvent ASA's overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Oncoinvent ASA (CHIX:ONCINO), the current EV-to-EBITDA is -1.57 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncoinvent ASA (CHIX:ONCINO) Overvalued in 2026?
Based on GuruFocus' analysis, Oncoinvent ASA stock appears to be undervalued.
The current stock price of kr1,039.91 is trading 91.3% below its estimated GF Value™ of kr11,980.43.
Key valuation signals for CHIX:ONCINO:
EV-to-EBITDA: -1.57
GF Value™: kr11,980.43 vs. price of kr1,039.91 (91.3% below fair value)
No single metric tells the full story. See the CHIX:ONCINO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. Its key product candidate is Radspherin, a receptor-independent alpha radiation therapy that leverages the anatomy of the abdominal cavity to destroy residual micrometastases using a single, localized dose of alpha radiation. Radspherin is currently in clinical development in two indications: peritoneal metastasis from ovarian and colorectal cancer, but it is also relevant for treating peritoneal metastasis from other cancer types and potentially metastatic cancer in other body cavities. Geographically, the company operates in Norway.
42GF Score
Get the complete analysis for CHIX:ONCINO
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ONCINO has been successfully added to your 
